MCID: FBR008
MIFTS: 49

Fibrillary Astrocytoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Fibrillary Astrocytoma

MalaCards integrated aliases for Fibrillary Astrocytoma:

Name: Fibrillary Astrocytoma 12 54 60 56 15 74
Diffuse Astrocytoma 12 54 60 6 74
Gemistocytic Astrocytoma 54 74
Protoplasmic Astrocytoma 54 74
Low-Grade Diffuse Astrocytoma 54
Fibrillary Astrocytic Tumors 12

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:6726
MeSH 45 D001254
NCIt 51 C4322
SNOMED-CT 69 71314006
ICD10 via Orphanet 35 C71.9
UMLS via Orphanet 75 C0280785 C0334582

Summaries for Fibrillary Astrocytoma

Disease Ontology : 12 An astrocytoma that is characterized as a low grade astrocytoma and has material basis in neoplastic astrocytes.

MalaCards based summary : Fibrillary Astrocytoma, also known as diffuse astrocytoma, is related to gemistocytic astrocytoma and protoplasmic astrocytoma, and has symptoms including seizures, headache and motor manifestations. An important gene associated with Fibrillary Astrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and DNA damage_ATM/ATR regulation of G1/S checkpoint. The drugs Temozolomide and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone.

Wikipedia : 77 Fibrillary astrocytomas also called low-grade or diffuse astrocytomas, are a group of primary... more...

Related Diseases for Fibrillary Astrocytoma

Diseases related to Fibrillary Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 gemistocytic astrocytoma 34.2 GFAP IDH2
2 protoplasmic astrocytoma 33.9 GFAP IDH2 TP53
3 giant cell glioblastoma 29.9 GFAP IDH1 MGMT TP53
4 pilocytic astrocytoma 29.7 GFAP IDH1 KIAA1549
5 gliosarcoma 29.6 GFAP IDH1 MGMT TP53
6 pleomorphic xanthoastrocytoma 29.6 GFAP IDH1 MGMT TP53
7 glioblastoma 29.4 H3F3A IDH1 IDH2 MGMT TP53
8 glioblastoma multiforme 29.3 GFAP IDH1 MGMT TP53
9 glioma 29.3 H3F3A IDH1 IDH2 TP53
10 grade iii astrocytoma 28.9 GFAP IDH2 MGMT PCNA TP53
11 glioma susceptibility 1 28.7 GFAP H3F3A IDH1 IDH2 TP53
12 oligodendroglioma 28.7 GFAP IDH1 IDH2 MGMT PCNA TP53
13 astrocytoma 10.5
14 interval angle-closure glaucoma 10.4 IDH1 IDH2
15 adult oligodendroglioma 10.4 IDH1 IDH2
16 enchondroma 10.4 IDH1 IDH2
17 cytogenetically normal acute myeloid leukemia 10.4 IDH1 IDH2
18 chondroblastic osteosarcoma 10.4 IDH1 IDH2
19 multiple enchondromatosis, maffucci type 10.4 IDH1 IDH2
20 intraductal papilloma 10.4 IDH1 IDH2
21 spindle cell hemangioma 10.4 IDH1 IDH2
22 periosteal chondrosarcoma 10.4 IDH1 IDH2
23 diffuse infiltrative lymphocytosis syndrome 10.3 IDH1 IDH2
24 drug-induced mental disorder 10.3 IDH1 IDH2
25 drug psychosis 10.3 IDH1 IDH2
26 undifferentiated pleomorphic sarcoma 10.3 IDH1 IDH2
27 periosteal osteogenic sarcoma 10.3 IDH1 TP53
28 2-hydroxyglutaric aciduria 10.3 IDH1 IDH2
29 d-2-hydroxyglutaric aciduria 1 10.3 IDH1 IDH2
30 enchondromatosis, multiple, ollier type 10.2 IDH1 IDH2
31 testicular torsion 10.2 PCNA TP53
32 mature teratoma 10.2 PCNA TP53
33 pilocytic astrocytoma of cerebellum 10.2 IDH1 IDH2 KIAA1549
34 oral leukoplakia 10.2 PCNA TP53
35 suppressor of tumorigenicity 3 10.2 PCNA TP53
36 intracranial chondrosarcoma 10.2 IDH1 IDH2 TP53
37 gastric lymphoma 10.2 PCNA TP53
38 bile duct adenocarcinoma 10.2 IDH1 IDH2 TP53
39 extraventricular neurocytoma 10.2 GFAP IDH1
40 pineal parenchymal tumor of intermediate differentiation 10.2 ATRX IDH1
41 intrahepatic cholangiocarcinoma 10.2 IDH1 IDH2 TP53
42 cholangiocarcinoma 10.2 IDH1 IDH2 TP53
43 cerebellar astrocytoma 10.2 IDH1 KIAA1549 TP53
44 dysembryoplastic neuroepithelial tumor 10.2 GFAP IDH1
45 essential thrombocythemia 10.2 IDH1 IDH2 TP53
46 frontal convexity meningioma 10.2 GFAP TP53
47 gliofibroma 10.2 GFAP TP53
48 cerebral convexity meningioma 10.2 GFAP TP53
49 cellular ependymoma 10.2 GFAP TP53
50 meninges sarcoma 10.2 GFAP TP53

Graphical network of the top 20 diseases related to Fibrillary Astrocytoma:



Diseases related to Fibrillary Astrocytoma

Symptoms & Phenotypes for Fibrillary Astrocytoma

UMLS symptoms related to Fibrillary Astrocytoma:


seizures, headache, motor manifestations, sensory manifestations

Drugs & Therapeutics for Fibrillary Astrocytoma

Drugs for Fibrillary Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
2
Procarbazine Approved, Investigational Phase 2, Phase 3 671-16-9 4915
3
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
4
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Donepezil Approved Phase 3 120014-06-4 3152
7
Histamine Approved, Investigational Phase 3 51-45-6 774
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Dermatologic Agents Phase 3,Phase 1
13 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
14 Antimitotic Agents Phase 2, Phase 3,Phase 1
15 Anesthetics Phase 3
16 Anesthetics, Intravenous Phase 3
17 Narcotics Phase 3
18 Cola Phase 3,Phase 1
19 Analgesics, Opioid Phase 3
20 Central Nervous System Depressants Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 3,Phase 2
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3,Phase 2
24 Liver Extracts Phase 3,Phase 2,Phase 1
25 Anesthetics, General Phase 3
26 Cholinesterase Inhibitors Phase 3
27 Nootropic Agents Phase 3,Phase 2
28 Neurotransmitter Agents Phase 3,Early Phase 1,Not Applicable
29 Cholinergic Agents Phase 3
30 Gastrointestinal Agents Phase 3,Early Phase 1,Not Applicable
31 Antipruritics Phase 3
32 Histamine Antagonists Phase 3
33 Anti-Allergic Agents Phase 3
34
Histamine Phosphate Phase 3 51-74-1 65513
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
39
Hydroxyurea Approved Phase 2 127-07-1 3657
40
Everolimus Approved Phase 2,Phase 1 159351-69-6 70789204 6442177
41
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
42
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
43
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
46
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
47
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
48
Sodium Citrate Approved, Investigational Phase 2 68-04-2
49
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
50
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
2 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
5 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Active, not recruiting NCT00978458 Phase 3 temozolomide
6 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
7 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
8 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
9 Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma Completed NCT00002806 Phase 2 lomustine;procarbazine hydrochloride;vincristine sulfate
10 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
11 Everolimus in Treating Patients With Recurrent Low-Grade Glioma Completed NCT00823459 Phase 2 Everolimus
12 Temozolomide in Treating Patients With Low-Grade Glioma Completed NCT00313729 Phase 2 temozolomide
13 Irinotecan in Treating Patients With Recurrent Glioma Completed NCT00003134 Phase 2 irinotecan hydrochloride
14 Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00003616 Phase 1, Phase 2 irinotecan hydrochloride
15 Sunitinib in Treating Patients With Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
16 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
17 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
18 Bevacizumab in Recurrent Grade II and III Glioma Completed NCT01164189 Phase 2 Temozolomide
19 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
20 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
21 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
22 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
23 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
24 Imatinib Mesylate in Treating Patients With Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
25 Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma Completed NCT00004024 Phase 2
26 Temozolomide in Treating Patients With Progressive Low-Grade Glioma Completed NCT00003466 Phase 2 temozolomide
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
29 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
30 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2 Temozolomide
31 Temozolomide and Radiation Therapy in Treating Patients With Gliomas Active, not recruiting NCT00114140 Phase 2 Temozolomide
32 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Active, not recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
33 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
34 Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT00553150 Phase 1, Phase 2 everolimus;temozolomide
35 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
36 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Terminated NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
37 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
38 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
39 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
40 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
41 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
42 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
43 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
44 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
45 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
46 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
47 Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00509431 Phase 1 Erlotinib + Sirolimus
48 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
49 BCX-1777 in Treating Patients With Refractory Cancer Completed NCT00073944 Phase 1 forodesine hydrochloride
50 Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor Completed NCT00069940 Phase 1

Search NIH Clinical Center for Fibrillary Astrocytoma

Genetic Tests for Fibrillary Astrocytoma

Anatomical Context for Fibrillary Astrocytoma

MalaCards organs/tissues related to Fibrillary Astrocytoma:

42
Brain, Liver, Bone, Spinal Cord, Cerebellum, Kidney, Thyroid

Publications for Fibrillary Astrocytoma

Articles related to Fibrillary Astrocytoma:

(show all 49)
# Title Authors Year
1
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( 29393182 )
2018
2
A rare case of a molecular "adult-type" diffuse astrocytoma arising in a child. ( 29198071 )
2018
3
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. ( 29016996 )
2018
4
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. ( 29444314 )
2018
5
Seizure-Induced Increased 18F-DOPA Uptake in a Child With Diffuse Astrocytoma and Transient Brain MRI Abnormalities Related to Status Epilepticus. ( 29465492 )
2018
6
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. ( 29497819 )
2018
7
Tumor cell vanishing with radiological changes suggesting progression in IDH-mutated diffuse astrocytoma treated only with surgery. ( 30079885 )
2018
8
Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation. ( 29859360 )
2018
9
Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. ( 28699883 )
2017
10
"The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism? ( 28470341 )
2017
11
A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. ( 26375727 )
2016
12
Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. ( 26404554 )
2016
13
Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3. ( 28663993 )
2016
14
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT. ( 28480352 )
2016
15
Diffuse astrocytoma arising within a demyelinating plaque. ( 27033061 )
2016
16
Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. ( 26095141 )
2015
17
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. ( 26243269 )
2015
18
Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma. ( 25354913 )
2015
19
Diffuse astrocytoma initially presenting as a massive intracerebral hemorrhage: case report. ( 24418786 )
2015
20
Synchronous rosette-forming glioneuronal tumor and diffuse astrocytoma with molecular characterization: a case report. ( 24986181 )
2014
21
Supratentorial low-grade diffuse astrocytoma: medical management. ( 25173138 )
2014
22
The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines. ( 25256634 )
2014
23
Hemorrhagic Recurrence in Diffuse Astrocytoma without Malignant Transformation. ( 25408937 )
2014
24
Clinicopathological features in the recurrence of oligodendroglioma and diffuse astrocytoma. ( 22648019 )
2012
25
Focal cortical dysplasia coexisting with diffuse astrocytoma in childhood: a case report and reappraisal of the glial component in archival FCD cases. ( 21118400 )
2011
26
Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. ( 21214332 )
2011
27
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. ( 21343879 )
2011
28
Dysgeusia: an atypical and neglected psychiatric symptom induced by fibrillary astrocytoma. ( 21497786 )
2011
29
Gliosarcoma arising from a fibrillary astrocytoma. ( 21737284 )
2011
30
Delayed intracerebral radiation necrosis occurring a decade after conventional radiotherapy in a patient of diffuse astrocytoma. ( 21768679 )
2011
31
Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. ( 20044756 )
2010
32
Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum. ( 20860893 )
2010
33
Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma. ( 19240976 )
2009
34
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. ( 19543740 )
2009
35
Morphological changes and stress responses in neurons in cerebral cortex infiltrated by diffuse astrocytoma. ( 14719540 )
2003
36
An unusual tuberous sclerosis case presenting with fibrillary astrocytoma. ( 12187056 )
2002
37
Differentiation between reactive gliosis and diffuse astrocytoma by in situ hybridization. ( 11342694 )
2001
38
Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival. ( 11556747 )
2001
39
BCL2 and BAX mRNA concentration profile in fibrillary astrocytoma. ( 11820596 )
2001
40
Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. ( 10785254 )
2000
41
A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. ( 11013373 )
2000
42
Genetic heterogeneity and progression in different areas within high-grade diffuse astrocytoma. ( 10601603 )
2000
43
Fibrillary astrocytoma in a goat: pathologic, immunohistochemical, and ultrastructural study. ( 8844587 )
1996
44
Intrasellar presentation of a cystic optic chiasm fibrillary astrocytoma. ( 9309792 )
1996
45
Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. ( 1902506 )
1991
46
Correlation of computed tomography and postmortem findings of a diffuse astrocytoma: a case report. ( 2598161 )
1989
47
Glial fibrillary acidic protein (GFAP): purification from human fibrillary astrocytoma, development and validation of a radioimmunoassay for GFAP-like immunoactivity. ( 438840 )
1979
48
Fibrillary astrocytoma at the base of the skull in a 5 1/2-year-old girl. ( 904938 )
1977
49
Crystal formations in ultrastructure of fibrillary astrocytoma. ( 5973794 )
1966

Variations for Fibrillary Astrocytoma

ClinVar genetic disease variations for Fibrillary Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DICER1 NM_177438.2(DICER1): c.1883A> C (p.Asn628Thr) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 95582028: 95582028
2 DICER1 NM_177438.2(DICER1): c.1883A> C (p.Asn628Thr) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 95115691: 95115691

Expression for Fibrillary Astrocytoma

Search GEO for disease gene expression data for Fibrillary Astrocytoma.

Pathways for Fibrillary Astrocytoma

Pathways related to Fibrillary Astrocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.84 ATRX H3F3A MGMT
2 10.97 PCNA TP53
3 10.66 PCNA TP53
4 10.42 PCNA TP53
5
Show member pathways
9.74 IDH1 IDH2

GO Terms for Fibrillary Astrocytoma

Cellular components related to Fibrillary Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromosome, telomeric region GO:0000784 8.8 ATRX H3F3A PCNA

Biological processes related to Fibrillary Astrocytoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.67 ATRX MGMT PCNA TP53
2 tricarboxylic acid cycle GO:0006099 9.51 IDH1 IDH2
3 cellular response to ionizing radiation GO:0071479 9.49 MGMT TP53
4 positive regulation of DNA repair GO:0045739 9.48 MGMT PCNA
5 replication fork processing GO:0031297 9.46 ATRX PCNA
6 DNA replication-independent nucleosome assembly GO:0006336 9.43 ATRX H3F3A
7 DNA methylation GO:0006306 9.4 ATRX MGMT
8 2-oxoglutarate metabolic process GO:0006103 9.32 IDH1 IDH2
9 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.26 ATRX TP53
10 NADP metabolic process GO:0006739 9.16 IDH1 IDH2
11 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
12 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Fibrillary Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NAD binding GO:0051287 9.32 IDH1 IDH2
2 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.26 IDH1 IDH2
3 histone acetyltransferase binding GO:0035035 9.16 PCNA TP53
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
5 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Fibrillary Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....